Intellia’s CRISPR drug snags orphan tag
To view this email as a web page, click here

Today's Rundown

Featured Story

Venatorx hits goal in antibiotic phase 3, clearing path to FDA

Venatorx Pharmaceuticals’ mission to start restocking the thinning cupboard of antibiotics has advanced. With its experimental candidate hitting the primary endpoint in phase 3, Venatorx is preparing to file for FDA approval in patients with urinary tract infections by the end of the year.

read more

Top Stories

Moderna doses 2nd arm of phase 2 booster study combining Spikevax with omicron-busting shot

The second arm of Moderna’s omicron booster trial has gotten underway with a first patient dosed in the phase 2 study testing a variant-specific vaccine against COVID-19.

read more

Intellia's CRISPR-engineered cell therapy secures FDA orphan drug status after AML trial launch

Intellia Therapeutics' first ex vivo cell therapy, which uses the famed CRISPR-Cas9 gene editing technology, received orphan drug designation from the FDA, unlocking tax credits and potentially seven years of exclusivity should the treatment snag the agency's approval.

read more

Morningside rolls up a pair of biotechs to birth clinical-phase inflammatory disease player

Morningside Ventures has rolled up two of its own biotechs to spawn a new startup, combining an Irish microbiome business and a U.S. neutrophil biology specialist to create inflammatory disease player Adiso Therapeutics.

read more

Selecta back in phase 1 gene therapy saddle after clinical hold lift, plans to reboot ‘expeditiously’

The FDA has lifted the clinical hold on Selecta Bioscience’s gene therapy to treat methylmalonic acidemia, a rare disease in children that affects metabolism. The company is now back in the saddle as it preps for a phase 1 trial.

read more

Roche-partnered Scenic Biotech snags $31M to study 3 rare disease drugs

Scenic Biotech has scored a $31 million series A financing round and plans to take three drugs into the clinic with a focus on rare genetic diseases.  The biotech already has a $375 million deal.

read more

Moderna CEO’s pay jumps 41% to $18.2M as COVID vaccine giant expands globally

Moderna’s business took flight in 2021 thanks to authorizations for its COVID-19 vaccine, and so did its CEO’s pay. CEO Stephane Bancel could be up for bigger pay checks in the future as Moderna has changed its compensation peer group with additions of several Big Pharma companies.

read more

Adaptive Biotechnologies lays off 12% of workforce to narrow immunosequencing tech

About 100 workers are being laid off as Adaptive reorganizes its business, homing in on just two core areas that can be served by its immune system-focused genetic sequencing technology.

read more

Novartis puts contract manufacturing ambitions on display with deal to produce Carisma's cell therapy

It turns out Novartis has a taste for the contract manufacturing business. After inking a slate of pandemic production pacts last year, the Swiss pharma is back for another—and this time, it’s looking beyond COVID-19.

read more

Gilead to boost West Coast production muscle after revealing New Jersey layoffs

The biotech has closed a deal for 27 acres of undeveloped land near its existing facility in Oceanside, California, which it will use to stand up additional manufacturing in the area. The company’s current Oceanside outfit supports clinical manufacturing and process development for Gilead and Kite Pharma, the exec said.

read more

ViVE 2022: How female founders, executives are driving the future of health tech

MIAMI—International Women's Day was Tuesday and at the ViVE 2022 conference this week, the impact of female founders and executives touched almost every conversation about the future of healthcare and tech.

read more

How a common cancer immunotherapy target might also hold the key to tackling obesity

The PD-L1 protein is a popular target for cancer immunotherapies, as tumors use it like a “brake” to dampen immune responses against them. But scientists from Germany and Ireland have evidence that the protein may also act as a protector against obesity.

read more

Resources

Whitepaper: The Long Game of Strategic Relationship Building with Medical Experts

Read why many MSLs are still challenged in developing integrated strategies to increase the volume of meaningful engagements. Download this industry report to find out what the top challenges are and suggestion strategies to solve them. Download now.

eBook: EMEA Regulatory Roadblocks around Decentralized Trials

Learn about ways to break down regulatory roadblocks and get closer to 100% clarity on regulatory positions to advance decentralized clinical trials in research.

Whitepaper: Top 5 Challenges Of Decentralized Clinical Trials And How To Overcome Them

How to overcome top challenges faced in decentralized trials.

Paid Marketplace: United Cargo: Providing comprehensive solutions for the most critical shipments

The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now.

Whitepaper: Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Whitepaper: Versatility of Softgel Technology - Encapsulation of a Volatile Compound

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

Whitepaper: The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Whitepaper: The CNS Market: 2021 Year in Review & Outlook for 2022

What’s in store for the CNS therapeutics market in 2022? This paper looks ahead in Alzheimer’s, Parkinson’s, DMD, psychiatric disorders, pain, and more.

Webinar: The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Whitepaper: Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Events